Literature DB >> 26822658

[Prevalence of chronic obstructive pulmonary disease among community population aged ≥40 in China: a Meta-analysis on studies published between 1990 and 2014].

Heling Bao1, Liwen Fang, Linhong Wang.   

Abstract

OBJECTIVE: To understand the prevalence of chronic obstructive pulmonary disease (COPD) among the community population aged ≥40 years in China from 1990 to 2014.
METHODS: The studies on the prevalence of COPD among the community population in China published from 1990 to 2014 were retrieved from the following databases: Chinese BioMedical Literature Database (CBM), Chinese Journal Full-text Database (CNKI), Wanfang Database, PubMed and EBSCO. Mantel-Haenszel fixed effect and random effect model and software Stata were used for statistical analysis.
RESULTS: A total 30 studies were included in the Meta analysis. The pooled prevalence of COPD was 9.9%(95%CI: 8.8%-11.0%). The prevalence was higher in males (13.0%, 95%CI: 11.5%-14.4%) than in females (5.8%, 95% CI: 4.9%-6.6%), and the prevalence of COPD increased with age obviously from 3.2% in age group 40-49 years (95%CI: 2.5%-3.9%) to 20.3% in age group ≥70 years (95%CI: 18.2%-22.4%). The differences in prevalence among different areas had no statistical significance.
CONCLUSIONS: The prevalence of COPD in population aged ≥40 years increased gradually in China in recent 20 years. Obvious heterogeneity was found among the results of the studies due to the different diagnostic standards and sample sizes.

Entities:  

Mesh:

Year:  2016        PMID: 26822658     DOI: 10.3760/cma.j.issn.0254-6450.2016.01.026

Source DB:  PubMed          Journal:  Zhonghua Liu Xing Bing Xue Za Zhi        ISSN: 0254-6450


  8 in total

1.  Ulinastatin protects the lungs of COPD rats through the HMGB1/TLR4 signaling pathway.

Authors:  Wei Liu; Zhiguang Liu; Weidong Zhang; Shaoxi Cai
Journal:  Oncol Lett       Date:  2018-07-11       Impact factor: 2.967

2.  Healthy lifestyle behaviors among individuals with chronic obstructive pulmonary disease in urban and rural communities in China: a large community-based epidemiological study.

Authors:  Ruohua Yan; Yang Wang; Jian Bo; Wei Li
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-11-13

3.  Experiences of a health coaching self-management program in patients with COPD: a qualitative content analysis.

Authors:  Lan Wang; Jan Mårtensson; Yue Zhao; Annette Nygårdh
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-05-11

4.  Investigation of the Prevalence and Diagnosis of Chronic Obstructive Pulmonary Disease in a Group of Elderly Individuals Residing in an Island Area of Ningbo.

Authors:  Wei Sheng; Youchang Huang; Zaichun Deng; Hongying Ma
Journal:  Can Respir J       Date:  2019-08-01       Impact factor: 2.409

5.  Chronic obstructive pulmonary disease in China: a nationwide prevalence study.

Authors:  Liwen Fang; Pei Gao; Heling Bao; Xun Tang; Baohua Wang; Yajing Feng; Shu Cong; Juan Juan; Jing Fan; Ke Lu; Ning Wang; Yonghua Hu; Linhong Wang
Journal:  Lancet Respir Med       Date:  2018-04-09       Impact factor: 30.700

6.  Prevalence and Risk Factors for COPD at High Altitude: A Large Cross-Sectional Survey of Subjects Living Between 2,100-4,700 m Above Sea Level.

Authors:  Yanfei Guo; Zhenzhen Xing; Guangliang Shan; Jean-Paul Janssens; Tieying Sun; Di Chai; Weiming Liu; Yuxia Wang; Yali Ma; Yaqi Tong; Yilin Huang; Yang Cao; Chen Wang
Journal:  Front Med (Lausanne)       Date:  2020-12-03

7.  Expression of Matrix Metalloproteinase-2, Matrix Metalloproteinase-9, Tissue Inhibitor of Metalloproteinase-1, and Changes in Alveolar Septa in Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Yongxiang Zhang; Yuechuan Li; Zhen Ye; Hui Ma
Journal:  Med Sci Monit       Date:  2020-10-18

8.  Potential clinical and economic impact of optimised maintenance therapy on discharged patients with COPD after hospitalisation for an exacerbation in China.

Authors:  Ahmed Salem; Heng Zhong; Mafalda Ramos; Mark Lamotte; Hao Hu
Journal:  BMJ Open       Date:  2021-04-28       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.